MedTrace Logo

A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer

NCT02228785 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2014-08-29

No results posted yet for this study

Summary

This study was designed to investigate the safety and tolerance of three doses (100µg, 200µg, 500µg) of G17DT for the treatment of patients with colorectal cancer.

Conditions

Interventions

BIOLOGICAL

G17DT

Sponsors & Collaborators

  • Cancer Advances Inc.

    lead INDUSTRY

Principal Investigators

  • J D Hardcastle, MChir, FRCP, FRCS · University of Nottingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-05-31
Primary Completion
1994-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228785 on ClinicalTrials.gov